BOSTON (GenomeWeb News) — Oxford Gene Technology has closed one of its business units as it concentrates on developing and launching new microarray products and growing its licensing revenue in newer markets like Japan, according to a company official.

 

OGT's CEO Mike Evans said this week that OGT had decided to close down the unit, called Tridend, because it "didn't fit with OGT's core strategy." Evans spoke with GenomeWeb News at IBC Life Sciences' Discovery 2 Diagnostics conference, held here this week.